Recently when we talked to Dr. Amiji from Northeastern University, Boston, he says regarding drug targeting by using nanosystems...

"Most investigators do not concern themselves with what will happen to the nanosystems once it accomplishes its function. How will it be cleared from the body? Appropriate pharmacokinetic considerations need to be included in nanosystems design and in vivo testing is going to be absolutely critical, if we envision any kind of success".

for full interview visit

http://www.nanopharmaceuticals.o.../ Interview.html
Kumaresh Soppimath | Homepage | 04.05.06 - 5:45 pm | #